Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2021, Vol. 48 Issue (2): 343-346    DOI: 10.31083/j.ceog.2021.02.2319
Original Research Previous articles | Next articles
Maternal serum pregnancy-associated plasma protein-A concentration at 11–14 weeks of gestation of women with common congenital anatomic uterine abnormalities
Sotirios Sotiriou1, *(), Maria Satra2, Dimitra N. Vamvakopoulou3, Chrisostomos Sofoudis4, Aikaterini Simou5, Thomas Kilindris6, Andreas Sidiropoulos2, Konstantinos V. Kakavas7, Antonis Garas5, Hara Skentou1, Nikos C. Vamvakopoulos2, Alexandros Daponte5
1Laboratory of Histology and Embryology, School of Health Sciences, Faculty of Medicine, University of Thessaly, GR-41500 Larissa, Greece
2Laboratory of Biology, School of Health Sciences, Faculty of Medicine, University of Thessaly, GR-41500 Larissa, Greece
3Department of Pediatrics and Neonatology, School of Health Sciences, Faculty of Medicine, University of Thessaly, GR-41500 Larissa, Greece
4Deptartment of Obstetrics and Gynecology, Konstandopoulio General Hospital, GR-11472 Athens, Greece
5Department of Obstetrics and Gynaecology, School of Health Sciences, Faculty of Medicine, University of Thessaly, GR-41500 Larissa, Greece
6Laboratory of Medical Informatics, School of Health Sciences, Faculty of Medicine, University of Thessaly, GR-41500 Larissa, Greece
7Laboratory of Environmental quality and human health, Department of Environment, University of Thessaly, GR-41500 Larissa, Greece
Download:  PDF(171KB)  ( 76 ) Full text   ( 6 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objectives: To evaluate maternal serum pregnancy-associated plasma protein-A (PAPP-A) levels at 11–14 weeks of gestation in women with common congenital anatomic uterine abnormalities (AUAs). Methods: First trimester screening markers were compared between 12 AUA pregnancies and 60 age matched controls. Results: PAPP-A level and birth weight were significantly lower in AUA compared to control pregnancies (P < 0.001). Conclusion: Our findings suggest that AUA pregnancies are associated with low first trimester maternal serum PAPP-A concentrations.
Key words:  Pregnancy-associated plasma protein A      PAPP-A      Congenital anatomic uterine abnormalities      AUA     
Submitted:  08 October 2020      Revised:  23 November 2020      Accepted:  25 November 2020      Published:  15 April 2021     
*Corresponding Author(s):  Sotirios Sotiriou     E-mail:  sotiriousoti@yahoo.gr

Cite this article: 

Sotirios Sotiriou, Maria Satra, Dimitra N. Vamvakopoulou, Chrisostomos Sofoudis, Aikaterini Simou, Thomas Kilindris, Andreas Sidiropoulos, Konstantinos V. Kakavas, Antonis Garas, Hara Skentou, Nikos C. Vamvakopoulos, Alexandros Daponte. Maternal serum pregnancy-associated plasma protein-A concentration at 11–14 weeks of gestation of women with common congenital anatomic uterine abnormalities. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 343-346.

URL: 

https://ceog.imrpress.com/EN/10.31083/j.ceog.2021.02.2319     OR     https://ceog.imrpress.com/EN/Y2021/V48/I2/343

No related articles found!
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] Sandeep K. Krishnan, Norman E. Lepor. Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management[J]. Reviews in Cardiovascular Medicine, 2016, 17(S1): 9 -21 .
[3] Ibrahim Sidiqi, Patrick Alexander. Current Advances in Endovascular Therapy for Infrapopliteal Artery Disease[J]. Reviews in Cardiovascular Medicine, 2015, 16(1): 36 -50 .
[4] Prakash C. Deedwania. Management of Patients With Stable Angina and Type 2 Diabetes[J]. Reviews in Cardiovascular Medicine, 2015, 16(2): 105 -113 .
[5] Peter Shalit. Management of Dyslipidemia in Patients With Human Immunodeficiency Virus[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 38 -46 .
[6] Sophie Mavrogeni, Fabrizio Cantini, Gerald M. Pohost. Systemic Vasculitis: An Underestimated Cause of Heart Failure—Assessment by Cardiovascular Magnetic Resonance[J]. Reviews in Cardiovascular Medicine, 2013, 14(1): 49 -55 .
[7] George L. Smith. Appropriate Use Criteria: The Gold Standard, or a Mechanism for the Derogation of Clinical Judgment?[J]. Reviews in Cardiovascular Medicine, 2011, 12(2): 105 .
[8] Jeffrey W. Moses, Stephane Carlier, Issam Moussa. Lesion Preparation Prior to Stenting[J]. Reviews in Cardiovascular Medicine, 2004, 5(S2): 16 -21 .
[9] Dean J. Kereiakes. Coronary Small-Vessel Stenting in the Era of Drug Elution[J]. Reviews in Cardiovascular Medicine, 2004, 5(S2): 34 -45 .
[10] Steven V. Edelman. The Role of the Thiazolidinediones in the Practical Management of Patients With Type 2 Diabetes and Cardiovascular Risk Factors[J]. Reviews in Cardiovascular Medicine, 2003, 4(S6): 29 -37 .